Pregene / 普瑞金

The company operates on a model of integrating independent research and development with technology platformization and commercial internationalization. Pregene has established core technology platforms for nanobody screening, immune cell agent discovery, plasmid/viral vector development and production, and cell process development and manufacturing. Its business model includes both in-house drug development and providing translational and lentivirus manufacturing services to partners, generating revenue through licensing agreements, milestone payments, royalties, and CDMO services. A key product, PRG-1801, is a BCMA-targeted CAR-T cell therapy for treating relapsed/refractory multiple myeloma. This therapy received NMPA clinical approval in March 2020, marking the first for a CAR-T agent in the South China region. Pregene has entered into licensing agreements to develop and commercialize this therapy in Europe, the US, and India.

Investors include the National Small and Medium-sized Enterprise Development Fund, CAS Jiahe Fund, Haier Capital, and Shenzhen Capital Group. In November 2020, the company completed a Series B financing round of 140 million RMB and has since initiated its IPO process. The company's headquarters are in Shenzhen, China, with over 10,000 square meters of laboratory and GMP plant facilities.